The pathogenesis of Alzheimer's disease (AD) is characterized by cerebral deposits of amyloid ß-peptides (Aß) and neurofibrillary tangles which are surrounded by inflammatory cells. Long-term uses of non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of developing AD and delay the onset of the disease. In the present study, we used fluorescence spectroscopy with thioflavin T and electron microscopy to examine the effects of NSAIDs such as ibuprofen, aspirin, meclofenamic acid sodium salt, diclofenac sodium salt, ketoprofen, flurbiprofen, naproxen, sulindac sulfide and indomethacin on the formation, extension, and destabilization of ß-amyloid fibrils (fAß) at pH 7.5 at 37˚C in vitro. All examined NSAIDs dose-dependently inhibited formation of fAß from fresh Aß(1-40) and Aß(1-42), as well as their extension. Moreover, these NSAIDs dose-dependently destabilized preformed fAßs. The overall activity of the molecules examined was in the following order: ibuprofen ≈ sulindac sulfide ≥ meclofenamic acid sodium salt > aspirin ≈ ketoprofen ≥ flurbiprofen ≈ diclofenac sodium salt > naproxen ≈ indomethacin. Although the mechanisms by which these NSAIDs inhibit fAß formation from Aß, and destabilize preformed fAß in vitro are still unclear, NSAIDs may be promising for the prevention and treatment of AD. Keywords: Alzheimer's disease; ß-amyloid fibrils; electron microscopy; non-steroidal anti-inflammatory drugs; thioflavin T. M. Hirohata et al. for Neuropharmacology 3
Introduction
In the pathogenesis of Alzheimer's disease (AD), the abundance of intraneural neurofibrillary tangles and the extracellular deposition of the amyloid ß-peptide (Aß) as amyloid plaques and vascular amyloid are seminal events (Selkoe, 2001) . The aggregation of Aß and ß-sheet formation are considered to be critical events that render these peptides neurotoxic (Pike et al., 1995) . The presence of chronic neuroinflammation also contributes to the protracted degenerative course of AD (McGeer and McGeer, 1995) , and it is also common to other neurodegenerative disorders, such as Parkinson's disease and Creutzfelt-Jacob disease (Eikelenboom et al., 2002; Gao et al., 2003) . A chronic inflammatory response characterized by activated microglia, reactive astrocytes, complement factors, and increased inflammatory cytokine expression associated with Aß deposits has been described in the brain of AD patients (Rogers et al., 1996) . A number of epidemiological studies have demonstrated a reduced risk for AD in population with long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) in t'Veld et al., 1998; Akiyama et al., 2000; in t'Veld et al., 2001) . These epidemiological findings have been supported by experimental studies. First, chronic ibuprofen (Ibu) treatment significantly diminished amyloid deposition (Lim et al., 2000) , and improved behavioral impairment in the APPsw transgenic mouse (Tg2576) (Lim et al., 2001) . Second, a subset of NSAIDs such as Ibu, sulindac sulfide (SSide), indomethacin (Ind) (Weggen et al., 2001) and flurbiprofen (Flu) selectively decreased the secretion of Aß(1-42) from cultured cells independently of cyclooxygenase (COX) activity and lowered the amount of soluble in the brains of Tg2576 mouse. Third, SSide and enantiomers of Flu have been reported to target γ-secretase and preferentially reduce generation (Takahashi et al., 2003; Eriksen et al., 2003) .
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However, except the preliminary study where Thomas et al. (2001) used the non-physiological short peptide , the effects of NSAIDs on the formation and destabilization of Alzheimer's ß-amyloid fibrils (fAß) in vitro have not been studied in detail.
Using a nucleation-dependent polymerization model explaining the mechanism of fAß formation in vitro (Jarrnet and Lansbury, 1993; Naiki and Gejyo, 1999) , we previously found that nordihydroguaiaretic acid (NDGA) and rifampicin (Rif) inhibit fAß formation from Aß and fAß extention dose-dependently (Naiki et al., 1998) . Moreover, we reported that they also destabilize fAß(1-40) and fAß(1-42) in a concentration-dependent manner within a few hours at pH 7.5 at 37˚C, based on fluorescence spectroscopic analysis with thioflavin T (ThT) and electron microscopic studies (Ono et al., 2002b) .
Here, we examined the effects of the major NSAIDs on the formation, extension, and destabilization of fAß(1-40) and fAß(1-42) at pH 7.5 and 37˚C in vitro, using fluorescence spectroscopy with ThT and electron microscopy.
Methods

Preparation of Aß and fAß solutions
Aß(1-40) (trifluoroacetate salt, lot number 540111 and 530108, Peptide Institute Inc., Osaka, Japan) and Aß(1-42) (trifluoroacetate salt, lot number 540127 and 530914, Peptide Institute Inc., Osaka, Japan) were dissolved by brief vortexing in 0.02% ammonia solution at a concentration of 500 µM (2.2 mg/mL) and 250 µM, respectively, in a 4˚C room and stored at -80˚C before assaying (fresh and Aß(1-42) solutions). fAß(1-40) and fAß(1-42) were formed from the fresh Aß(1-40) and
Aß(1-42) solutions, respectively, sonicated, and stored at 4˚C as described elsewhere (Hasegawa et al., 1999) .
Fresh, non-aggregated fAß(1-40) and fAß(1-42) were obtained by extending sonicated fAß(1-40) or fAß(1-42) with fresh Aß(1-40) or Aß(1-42) solutions, respectively, just before the destabilization reaction (Ono et al., 2002a; 2002b) . The reaction mixture was 600 µL and contained 10 µg/mL (2.3 µM) fAß(1-40) or fAß(1-42), 50 µM or , 50 mM phosphate buffer, pH 7.5, and 100 mM NaCl. After incubation at 37˚C for 3-6 h under non-agitated conditions, the extension reaction proceed to equilibrium as measured by the fluorescence of ThT. In the following experiment, the concentration of fAß(1-40) and fAß(1-42) in the final reaction mixture was regarded as 50 µM.
Fluorescence spectroscopy, electron microscopy, and polarized light microscopy.
A fluorescence spectroscopic study was performed as described by Naiki and Nakakuki (1996) 
on a
Hitachi F-2500 fluorescence spectrophotometer (Tokyo, Japan). Optimum fluorescence measurement of fAß(1-40) and fAß(1-42) were obtained at the excitation and emission wavelengths of 445 and 490 nm, respectively, with the reaction mixture containing 5 µM ThT (Wako Pure Chemical Industries Ltd, Osaka, Japan) and 50 mM of glycine-NaOH buffer, pH 8.5. An electron microscopic study and polarized light microscopic study of the reaction mixtures were performed as described elsewhere 6 (Hasegawa et al., 1999) .
Polymerization assay
Polymerization of Aß with or without fAß added as seeds was assayed as described elsewhere (Naiki et al., 1998) . The reaction mixture contained 50 µΜ , or 25 or 50 µΜ Aß(1-42), 0 or 10 µg/mL fAß(1-40) or fAß(1-42), 0, 0.01, 0.1, 1, 10, or 50 µΜ NSAIDs (Ibu, aspirin (Asp), meclofenamic acid sodium salt (Mec), diclofenac sodium salt (Dic), ketoprofen (Ket), Flu, naproxen (Nap), SSide, Ind), NDGA, Rif, or nicotine (Sigma Chemical Co., St. Louis, MO, USA), 1% dimethyl sulfoxide (DMSO) (Nacakai Tesque, Inc., Kyoto, Japan), 50 mΜ phosphate buffer, pH 7.5, and 100 mΜ NaCl. NSAIDs dissolved in DMSO at concentrations of 1, 10, 100 µM, 1 mΜ and 5 mΜ, were added to the reaction mixture to make the final concentration 0.01, 0.1, 1, 10 µΜ and 50 µΜ, respectively.
Aliquots (30 µL) of the mixture were put into oil-free PCR tubes (size: 0.5 mL, code number: 9046; Takara Shuzo Co. Ltd, Otsu, Japan). The reaction tubes were then put into a DNA thermal cycler (PJ480; Perkin Elmer Cetus, Emeryville, CA, USA). The plate temperature was elevated at maximal speed, starting at 4˚C, to 37˚C. Incubation times ranged between 0 and 8 days (as indicated in each figure), and the reaction was stopped by placing the tubes on ice. The reaction tubes were not agitated during the reaction. From each reaction tube, triplicate 5 µL aliquots were removed, then subjected to fluorescence spectroscopy and the mean of each triplicate determined. In the ThT solution, the concentration of NSAIDs examined in this study was diluted up to 1/200 of that in the reaction mixture.
We confirmed that these compounds did not quench ThT fluorescence at the diluted concentration (data not shown).
Destabilization assay
Destabilization of fAß was assayed as described elsewhere (Ono et al., 2002b) . Briefly, the reaction mixture contained 25 µM fresh fAß(1-40) or fAß(1-42), 0, 0.01, 0.1, 1, 10 or 50 µΜ NSAIDs, NDGA, Rif, or nicotine, 1% DMSO, 50 mΜ phosphate buffer, pH 7.5, 100 mΜ NaCl, and 1% (wt/vol) polyvinyl alcohol (Wako Pure Chemical Industries Ltd) to avoid the aggregation of fAß and the adsorption of fAß onto the inner wall of the tube during the reaction.
After being mixed by pipetting, triplicate 5 µL aliquots were subjected to fluorescence spectroscopy and 30 µL aliquots were put into oil-free PCR tubes (Takara Shuzo Co. Ltd, Otsu, Japan). The reaction tubes were then transferred into a DNA thermal cycler (Perkin Elmer Cetus, Emeryville, California). Starting at 4˚C, the plate temperature was elevated at maximal speed to 37˚C.
Incubation times ranged from 0 to 24 h (as indicated in each figure), and the reaction was stopped by placing the tubes on ice. The reaction tubes were not agitated during the reaction. From each reaction tube, 5 µL aliquots in triplicate were subjected to fluorescence spectroscopy and the mean of the three measurements was determined. ThT fluorescence did not change significantly when fAß were incubated with 0-50 µM of NSAIDs at either 4˚C or 37˚C for 1 min, then subjected to ThT assay, indicating that these compounds did not compete with ThT for fAß (data not shown).
Other analytical procedures
Protein concentrations of Aßs and fAßs in the reaction mixtures were determined by the method of Bradford (1976) with a protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA). The solution quantified by amino acid analysis was used as the standard. The linear least squares fit and one-way analysis of variance, post-hoc test by Scheffe were used for statistical analysis.
Results
Effect of NSAIDs on the kinetics of fAß polymerization
As shown in Fig. 1A -D, the fluorescence of ThT followed a characteristic sigmoidal curve when fresh Aß(1-40) or Aß(1-42) was incubated at 37˚C. This curve is consistent with a nucleation-dependent polymerization model (Jarrett and Lansbury, 1993; Naiki and Gejyo, 1999) .
Fresh fAß(1-40) assumed a non-branched, helical filament structure of approximately 10 nm width and exhibited a helical periodicity of approximately 220 nm. In the fresh fAß(1-42) solution, two types of filaments of approximately 8 and 12 nm width were observed. Although the Aß batches used here were different from those in our previous experiments, these morphologies of fAßs were similar to those reported previously (Naiki and Nakakuki, 1996; Naiki et al., 1998) . Both fAß(1-40) and fAß(1-42) stained with Congo red showed typical orange-green birefringence under polarized light.
The final equilibrium level of Aß(1-40) or Aß(1-42) was lowered dose-dependently by incubation with M. Hirohata et al. for Neuropharmacology 9 10 and 50 µM Ibu, Ket or Nap ( Fig. 1A-D ). Other NSAIDs (Asp, Mec, Dic, Flu, SSide and Ind) also significantly inhibited the polymerization of Aß(1-40) and Aß(1-42) (Fig. 6A, B ).
As shown in Fig. 2A -D, the fluorescence increased hyperbolically without a lag phase and proceeded to equilibrium much more rapidly by incubation of fresh Aß(1-40) or Aß(1-42) with fAß(1-40) or fAß(1-42), respectively, at 37˚C, than that without seeds (compare Fig. 1A, B, and 2A, B ).
This curve is consistent with a first-order kinetic model (Naiki and Nakakuki, 1996) . The final equilibrium level was dose-dependently decreased by incubation of Aß(1-40) or Aß(1-42) with fAß(1-40) or Aß(1-42), respectively, with 10 or 50 µM Ibu, Ket or Nap ( Fig. 2A-D ). Other NSAIDs (Asp, Mec, Dic, Flu, SSide and Ind) also significantly inhibited the extension of fAß(1-40) and fAß(1-42) (data not shown).
As shown in Fig. 2E , at a constant fAß(1-40) concentration, a good linearity was observed between the Aß(1-40) concentration and the initial rate of fAß(1-40) extension both in the presence and absence of Ibu. This linearity is again consistent with a first-order kinetic model and indicates that at each Aß(1-40) concentration, the net rate of fAß(1-40) extension is the sum of the rates of polymerization and depolymerization (Naiki and Nakakuki, 1996; Hasegawa et al., 2002) . In the presence of 10 µΜ Ibu, the slope of the straight line decreased to about 36%.
As shown in Fig. 3B , clear fibril extension was observed by electron microscopy when fresh Aß(1-40) was incubated with fAß(1-40) at 37˚C. However, 50 µM Ibu completely inhibited the extension of sonicated fAß(1-40) (Fig. 3A, C) . Ibu inhibited the extension of fAß(1-42) and other NSAIDs (Asp, Mec, Dic, Ket, Flu, Nap, SSide and Ind) also inhibited the extension of fAß(1-40) and fAß(1-42) (data not shown).
Effect of NSAIDs on the kinetics of fAß destabilization
As shown in Fig. 4A Ind) also significantly destabilized fAß(1-40) and fAß(1-42) (Fig. 6C, D) .
After incubation of 25 µM fresh fAß(1-40) with 50 µM Ibu for 1 h, many short, sheared fibrils were observed ( Fig. 5B) . At 6 h, the number of fibrils was markedly decreased, and small amorphous aggregates were occasionally observed (Fig. 5C ). Ibu destabilized fresh fAß(1-42) and other NSAIDs (Asp, Mec, Dic, Ket, Flu, Nap, SSide and Ind) also destabilized preformed fAß(1-40) and fAß(1-42) (data not shown).
As shown in Fig. 6 , statistical analysis revealed a significant difference in the potency of 50 µM NSAIDs for the anti-polymerization effect (A, B) and for the fibril destabilizing effect (C, D). In both the cases of fAß(1-40) and fAß(1-42), the potency of NSAIDs for the anti-polymerization effect was similar to that for the fibril-destabilizing effect. Additionally, similar anti-polymerization and fibril-destabilizing effects were observed for both fAßs. The overall activity of the molecules examined was in the order of: Ibu ≈ SSide ≥ Mec > Asp ≈ Ket ≥ Flu ≈ Dic > Nap ≈ Ind. We finally compared the anti-amyloidogenic and fibril-destabilizing activity of SSide and Ibu with that of NDGA,
Discussion
In this study, we demonstrated that various NSAIDs dose-dependently inhibited formation of fAß from fresh Aß(1-40) and , as well as their extension in vitro. Moreover, these NSAIDs dose-dependently destabilized preformed fAßs. Thomas et al. (2001) suggested that the anti-aggregation effect of NSAIDs may be due to their interaction with epitope 3-6 and/or 25-35 in Aß, which are considered crucial to Aß aggregation and neurotoxicity. As shown in Fig. 2E , the extension of fAß(1-40) followed a first-order kinetic model even in the presence of Ibu. The net rate of fAß(1-40) extension is the sum of the rates of polymerization and depolymerization (Naiki and Nakakuki, 1996; Hasegawa et al., 2002) . Thus, one possible explanation for the finding in Fig. 2E may be that Ibu bound to the ends of extending fAß(1-40) and increased the rate of depolymerization by destabilizing the conformation of which has just been incorporated into the fibril ends. Alternatively, Ibu would bind to Aß(1-40) and consequently decrease the rate of polymerization. Tomiyama et al. (1996) suggested that Rif binds to Aß by hydrophobic interactions between its lipophilic ansa chain and the hydrophobic region of Aß, thus blocking associations between Aß molecules leading to fAß formation. The anti-amyloidogenic and fibril-destabilizing activity of tetracycline (Tc), small-molecule anionic sulphonates or sulphates, melatonin, ß-sheet breaker peptides (iAß5) and nicotine may also be related to the propensity to bind to the specific sites of Aß (Kisilevsky et al. 1995; Soto et al. 1996; Pappolla et al. 1998; Forloni et al. 2001; Zeng et al. 2001 ). Thus, it may be reasonable to consider that NSAIDs could exhibit their anti-amyloidogenic and fibril-destabilizing effects by directly binding to Aßs and/or fAßs.
Taking into consideration the findings we obtained previously by systematic in vitro studies, we judged the overall activity of the anti-amyloidogenic molecules to be in the order of: tannic acid >> NDGA = wine-related polyphenols (myricetin, morin, quercetin) >> Rif = Tc > poly(vinylsulfonic acid, sodium salt) = 1,3-propanedisulfonic acid, disodium salt > iAß5 > nicotine (Ono et al., 2002a; 2002b; 2004a) . In this study, we observed that the activity of SSide and Ibu is similar to that of Rif (Fig.   7 ).
Next, we considered the structure-activity relationships of NSAIDs and other anti-amyloidogenic compounds. The antioxidant compounds with hydroxyphenyl rings are suggested to bind specifically to Aß and/or fAß, inhibit fAß formation and/or destabilize preformed fAß (Ono et al., 2002b; 2004a; 2004b; Li et al., 2004) . On the other hand, the NSAIDs examined in this study have no hydroxyphenyl rings (Fig. 8) . In general, these NSAIDs have an aromatic-based hydrophobic structure with some fused ring structures and methyl and/or carboxyl groups. This structure might be quite suitable for specifically binding to free Aß and subsequently inhibiting the polymerization of Aß into fAß. Alternatively, this structure might be suitable for a specific binding to fAß and subsequent destabilization of the ß-sheet rich conformation of Aß molecules in fAß. Further studies, such as nuclear magnetic resonance experiments, are essential to reveal the exact structure-activity relationships for NSAIDs and other organic compounds that exhibit anti-amyloidogenic and fibril-destabilizing effects in vitro.
Clinically, Ibu has been used in the treatment of nerve-root compression pain. Although their penetration into the cerebrospinal fluid (CSF) is 0.9-1.5 % of the plasma level, the CSF level of Ibu derivatives is the range 595-1241 ng h/ml in the patients taking oral doses of 800 mg Ibu (Bannwarth et al., 1995) . This corresponds to 2884-6016 µM h of Ibu, which were higher than the concentration used in the present study. It is therefore conceivable that therapeutic doses of Ibu could provide a concentration sufficient to achieve the anti-amyloidogenic effects.
Recent epidemiological studies have revealed that long-term and/or short-term use of some NSAIDs may protect against AD in t'Veld et al., 1998; Akiyama et al., 2000; in t'Veld et al., 2001) . Our study and several reports on the effects of NSAIDs may well explain this correlation. First, the major therapeutic effect of NSAIDs is believed to be due to their inhibition of COX-1 and COX-2, leading to the suppression of prostaglandin synthesis and chronic neuroinflammation contributing to the protracted degenerative course of AD (McGeer and McGeer, 1995; Akiyama et al., 2000) . Second, Weggen et al. (2001) recently suggested that a subset of NSAIDs including Ibu, SSide, Ind and R-Flu directly affect amyloid pathology in the brains of transgenic mouse by reducing the amount of soluble Aß(1-42) peptide levels independently of COX activity. They also suggested that NSAIDs subtly alter γ-secreatase activity without significantly perturbing other amyloid precursor protein (APP) pathways or Notch cleavage. Some NSAIDs were reported to lower Aß(1-42) levels selectively both in cultured cell and broken cell assays, suggesting that these compounds interact directly with the γ-secretase complex itself that generates Aß from human APP Eriksen et al., 2003) . In addition, a subset of NSAIDs can reduce through inhibition of Rho activity, which may regulate APP processing in a cell culture (Zhou et al., 2003) . Finally, as shown in this paper, NSAIDs dose-dependently inhibit fAß formation from fresh Aß and their extension, as well as destabilize preformed fAß in vitro. Thus, it may be reasonable to speculate that NSAIDs could prevent the development of AD, not only through suppressing chronic neuroinflammation and reducing the amount of soluble Aß(1-42) peptide levels, but also through directly inhibiting the deposition of fAß in the brain. In relation to the latter scenario, it may be essential to evaluate the effect of NSAIDs on the Aß oligomer formation in a future study, because the Aß oligomer has been reported to be the most neurotoxic form of all the Aß aggregates (Gong et al., 2003) . Yang et al. (2005) recently reported that curcumin prevented Aß42 oligomer formation and toxicity between 0.1 and 1.0 µM, which is consistent with our EC 50 values of curcumin for the anti-amyloidogenic and fibril-destabilizing activity (Ono et al., 2004b) . Although the exact mechanisms of anti-amyloidogenic and fibril-destabilizing activity of NSAIDs are unclear, the careful and safe use of them could contribute the prevention and therapy of AD and other kinds of human amyloidosis. 10, 20, 30, 40, , were incubated at 37˚C for 1 h. Points represent means of three independent experiments. In all points, standard errors were within symbols. Liner least-square fit was performed for each straight line (R 2 = 0.971 and 0.959 for ○ and •, respectively). Aß(1-40) and , respectively, and dose-dependent destabilization of fAß(1-40) (C) and fAß(1-42) (D). In (A) and (B), the reaction mixture containing 50 µM or 25 µM Aß(1-42), 50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 0, 0.01, 0.1, 1, 10 and 50 µM NDGA (•), Rif (■), SSide (□), Ibu (○), or nicotine (◆) were incubated at 37˚C for 4 days or 24 h, respectively. In (C) and (D), the reaction mixture containing 25 µM fAß(1-40) or fAß(1-42), 50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 0, 0.01, 0.1, 1, 10 and 50 µM NDGA (•), Rif (■), SSide (□), Ibu (○), or nicotine (◆) were incubated at 37˚C for 6 h. Each point represents the average of three independent experiments. SD is indicated by bars. The average without compounds was regarded as 100%.
Legends for figures
Note that the final equilibrium levels in the presence of 50 µM SSide and Ibu were different from those in Fig. 6 because different lots of Aß(1-40) and Aß(1-42) (530108 and 530914, respectively) were used in these experiments. 
